Advanced BioScience Laboratories

Slides:



Advertisements
Similar presentations
CEACHRUCNRSCPUINRAINRIAINSERMINSTITUT PASTEURIRD 1 CEACHRUCNRSCPUINRAINRIAINSERMINSTITUT PASTEURIRD Skin targeting for vaccine efficacy Laboratory of «
Advertisements

NIAID BioDefense Research: Challenges, Opportunities, & Sustainability
Let’s start with a story… In 1796 an English physician, Edward Jenner, attempted a very famous and risky experiment. In those days people used to die of.
Lecture 26. Prevention and Control -- Vaccines
Overview of the Division of Viral Products
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Immune Memory and Vaccines Great immune system review BookIMMUN.html#Immunity Figures from good immune.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Vaccines
Vaccine development: from idea to product Veronica Leautaud, Ph.D. rice.edu Keck Hall 224 / 232-lab Lecture 9 BIOE 301-Bioengineering and World Health.
Vaccination. NATURALLY ACQUIRED IMMUNITY Active: Acquired through contact with microorganisms (infection). Provides long term protection. Passive: Antibodies.
Disease: Edward Jenner
Vaccines Polio - close to eradication. In 2001 >1000 cases worldwide; last wild case in Americas in Peru in 1991.
Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.
HIV Vaccine Research & Development
Types of vaccines 1 - First generation vaccines are whole-organism vaccines - either live and weakened, or killed forms. [1] Live, attenuated vaccines,
Terry Kotrla, MS, MT(ASCP)BB
Viruses What are they? How do they work? Where do they come from? And… What good are they? Viruses.
Phagocyte. B cells Receptor B Cell Naïve B cell B cells and antibodies daughter cells produce antibodies phagocyte consumes an antibody coated virus.
HIV/AIDS vaccine development Lecture 10 Biomedical Engineering for Global Health.
Viruses What are they? How do they work? Where do they come from? And… What good are they? Viruses.
Vaccination. Vocabulary Check Vaccination: conferring immunity to a disease by injecting an antigen (of attenuated microorganisms or inactivated component)
Lesson Overview Lesson Overview Fighting Infectious Disease Lesson Overview 35.3 Fighting Infectious Disease.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Viruses Why are viruses considered non-living? Do they have organelles? Do they carry out life processes? –Grow, take in food, make waste? –How.
Lecture 15 Vaccines. History Turkey- smallpox from sick person into veins of well person Variolation- mortality rate- 1% Edward Jenner received.
Vaccine Manufacturing Joe Bielitzki NanoScience Technology Center University of Central Florida Orlando, Florida
VACCINES: PRINCIPLES & PRACTICE. What is a vaccine? - an antigenic preparation used to produce active immunity to a disease, in order to prevent or ameliorate.
Immune Memory and Vaccines B-cell activation and Memory B-cells Acquired Immunity –“natural” after infection or disease –“artificial” through vaccine Vaccines.
35.3 Fighting Infectious Disease
Vaccines: Historical Perspective  Immunity - state of protection from an infectious disease.  430 BC – Greek historian Thucydides - Athenian plague 
Vaccine development: from idea to product Lecture 9 Biomedical Engineering for Global Health.
New Technologies: the Role of the Private Sector Biotech’s Perspectives on Vaccine Development Alliances Peter Young CEO, AlphaVax, Inc.
The Immune System.
Pathology - the scientific study of the nature of disease and its causes A PATHOGEN is any disease causing agent. Quick Exercise: How many diseases can.
VAKSIN. INTRODUCTION AND HISTORY Vaccination can be defined as a deliberate attempt to induce protection against disease with the goal of inducing active.
Establishing a Global Vaccine Development Fund Peter Hale The Foundation for Vaccine Research Washington, DC Consultation on Financing of R&D Preparedness.
Microbiology Defination - Bacteriology: the study of bacteria
Human clinical trial of DNA-MVA HIV vaccine candidate begins A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector.
“28,424 cases of Ebola and still counting—what have we learned
Vaccine development: from idea to product Lecture 9 Biomedical Engineering for Global Health.
Edward Jenner ( ) – father of vaccination, developed a vaccine for smallpox.
Genetic DNA Vaccines By Chelsea Heimbrock. What are DNA Vaccines? An injection of genes of a virus into the body that creates an immune response for the.
Virus vaccines LECTURE 17: Viro100: Virology 3 Credit hours NUST Centre of Virology & Immunology Waqas Nasir Chaudhry.
$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.
Regulatory Perspective on Trends in Veterinary Biologics Byron Rippke, DVM Nancy Clough, DVM, PhD Director, Center for Veterinary Biologics U.S. Department.
Vaccination. immunity adaptive natural active passive artificial active passive innate.
HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.
Vaccines Combating Viruses. There are many different viral infections, most of which you have probably already heard of! List some viral infections that.
1 Considerations for Licensure of Next Generation Smallpox Vaccines Timothy Nelle, PhD Team Leader, Division of Vaccines and Related Applications Office.
Vaccines Dr. Sarah I. Bukhari 324 PHT PhD in Clinical Microbiology
VACCINOLOGY (BIO-301) Credit Hrs 3(2-1) Dr. Aneela javed.
Chapter 12-Vaccines Traditional vs. rDNA vaccines Subunit vaccines
Manipulation of the Immune Response Vaccination
Unit 4 - Immunology and Public Health
Chapter 7-Vaccines Vaccination Current and future vaccines
New Technologies in Vaccines
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Novel vaccine adjuvants for infectious diseases aninal
35.3 Fighting Infectious Disease
Case presentation of non-clinical and clinical development of vaccines
How Vaccines work.
35.3 Fighting Infectious Disease
Vaccine -.
Vaccinations.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
VIRUSES And PRIONS.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Presentation transcript:

Advanced BioScience Laboratories Vaccine Development Gerald R. Kovacs, Ph.D. Scientific Director Advanced BioScience Laboratories Maryland, USA

Vaccine design and development Vaccines work by mimicking disease agents and stimulating the immune system to build up defenses against them 2

History of Vaccines 1798 - Edward Jenner noted: Smallpox and Cowpox: Milkmaids frequently contracted cowpox which caused lesions similar to that smallpox Milkmaids who had cowpox almost never got smallpox Jenner’s experiment: Collected pus from cowpox sores Injected cowpox pus into boy named James Phipps Then injected Phipps with pus from smallpox sores Phipps did not contract smallpox First to introduce large scale, systematic immunization against smallpox 3

How do vaccines work? Live attenuated virus Carrier vaccines DNA vaccines Antigen presentation T-helper cell Antigen presentation Killer T cell Non-infectious vaccines B cell: antibodies (neutralize & bridge) …By inducing adaptive immunity & memory! 4

Vaccine Development IND EUA BLA 3-7 years 1-2 years 5-10 years Agent Antigen ID Vaccine Candidate Vaccine Characterization Preclinical GMP Manufacture Phase 1 Phase 2 Phase 3 Safety Phase 4 Animal Efficacy Model Development Pivotal Animal Efficacy Proof of Concept Feasibility Formulation Identity Purity Stability Risk Assessments Potency Toxicology Dosage Schedule Mech. of Action Markers Adjuvant GMP Production GLP Toxicology GCP Evaluation Quality Control Quality Assurance Regulatory Affairs 3-7 years 1-2 years 5-10 years

Probability of Success in Transition Probability of transition between each phase of development 57% 72% 71% 80% 79% Pre-Clinical Phase 1 Phase 2 Phase 3 BLA Market Cumulative probability of success through each phase 41% 32% 23% 18.4% 6

Vaccine Development Timeline From idea to approval can take decades and $100s of millions. 1967. FluMist concept published in Nature 1991. Developed with NIAID support and licensed to Wyeth 1995. Licensed to Aviron. 2003. Approved for use. Effective vaccines for many diseases (HIV, Malaria) elusive after substantial investment of resources

Ebola virus vaccines

Ebola Vaccines in Development Discovery Preclinical Phase 1 Phase 2 Phase 3 USAMRIID replicons and VLPs Bavarian Nordic MVA GSK ChAd3 GSK ChAd3 GSK ChAd3, Merck VSV, Placebo Protein Sciences subunit Profectus VSV Merck ∆G-VSV Novartis RNA Inovio DNA J&J/Bavarian Nordic P/B Vaxart Oral NovaVax VLP TJU Attenuated rabies vector Mapp BioP ZMapp

Emerging and Re-emerging Infectious Diseases

Future of Vaccines Public-Private Partnerships Continued research on host-pathogen responses Innovation and rational design of vaccines Use of systems biology Rapid and flexible production platforms Effective regulatory pathways Long term federal and private industry support

Thank You